The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections

Konstantin H. Müller, Denis E. Kainov, Karim El Bakkouri, Xavier Saelens, Jef K. De Brabander, Christian Kittel, Elisabeth Samm, Claude P. Muller

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE Cellular vacuolar ATPases (v-ATPase) play an important role in endosomal acidification, a critical step in influenza A virus (IAV) host cell infection. We investigated the antiviral activity of the v-ATPase inhibitor saliphenylhalamide (SaliPhe) and compared it with several older v-ATPase inhibitors concanamycin A, bafilomycin A1, (BafA) and archazolid B targeting the subunit c of the V 0 sector. EXPERIMENTAL APPROACH An in vitro assay was devised to quantify the anti-influenza effect of v-ATPase inhibitors by measuring green fluorescent protein fluorescence of a reporter IAV. These data were combined with cytotoxicity testing to calculate selectivity indices. Data were validated by testing v-ATPase inhibitors against wild-type IAV in vitro and in vivo in mice. KEY RESULTS In vitro SaliPhe blocked the proliferation of pandemic and multidrug resistant viruses at concentrations up to 51-fold below its cytotoxic concentrations. At essentially non-toxic concentrations, SaliPhe protected 62.5% of mice against a lethal challenge of a mouse-adapted influenza strain, while BafA at cytotoxic concentrations showed essentially no protection against infection with IAV (SaliPhe vs. BafA P < 0.001). CONCLUSIONS AND IMPLICATIONS Our results show that a distinct binding site of the proton translocation domain of cellular v-ATPase can be selectively targeted by a new generation v-ATPase inhibitor with reduced toxicity to treat influenza virus infections, including multi-resistant strains. Treatment strategies against influenza that target host cellular proteins are expected to be more resistant to virus mutations than drugs blocking viral proteins.

Original languageEnglish (US)
Pages (from-to)344-357
Number of pages14
JournalBritish Journal of Pharmacology
Volume164
Issue number2
DOIs
StatePublished - Sep 2011

Fingerprint

Vacuolar Proton-Translocating ATPases
Influenza A virus
Virus Diseases
Protons
Human Influenza
Viruses
Viral Proteins
Pandemics
Green Fluorescent Proteins
Infection
Orthomyxoviridae
Antiviral Agents
Fluorescence
Binding Sites
Mutation
saliphenylhalamide
Pharmaceutical Preparations

Keywords

  • archazolid B
  • bafilomycin A1
  • concanamycin A
  • H5N1
  • influenza A virus
  • pandemic H1N1
  • salicylihalamide A derivatives
  • saliphenylhalamide
  • v-ATPase
  • v-ATPase inhibitor

ASJC Scopus subject areas

  • Pharmacology

Cite this

The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. / Müller, Konstantin H.; Kainov, Denis E.; El Bakkouri, Karim; Saelens, Xavier; De Brabander, Jef K.; Kittel, Christian; Samm, Elisabeth; Muller, Claude P.

In: British Journal of Pharmacology, Vol. 164, No. 2, 09.2011, p. 344-357.

Research output: Contribution to journalArticle

Müller, Konstantin H. ; Kainov, Denis E. ; El Bakkouri, Karim ; Saelens, Xavier ; De Brabander, Jef K. ; Kittel, Christian ; Samm, Elisabeth ; Muller, Claude P. / The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. In: British Journal of Pharmacology. 2011 ; Vol. 164, No. 2. pp. 344-357.
@article{b8c6164bd2224ebd91ca6f05b008f37e,
title = "The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections",
abstract = "BACKGROUND AND PURPOSE Cellular vacuolar ATPases (v-ATPase) play an important role in endosomal acidification, a critical step in influenza A virus (IAV) host cell infection. We investigated the antiviral activity of the v-ATPase inhibitor saliphenylhalamide (SaliPhe) and compared it with several older v-ATPase inhibitors concanamycin A, bafilomycin A1, (BafA) and archazolid B targeting the subunit c of the V 0 sector. EXPERIMENTAL APPROACH An in vitro assay was devised to quantify the anti-influenza effect of v-ATPase inhibitors by measuring green fluorescent protein fluorescence of a reporter IAV. These data were combined with cytotoxicity testing to calculate selectivity indices. Data were validated by testing v-ATPase inhibitors against wild-type IAV in vitro and in vivo in mice. KEY RESULTS In vitro SaliPhe blocked the proliferation of pandemic and multidrug resistant viruses at concentrations up to 51-fold below its cytotoxic concentrations. At essentially non-toxic concentrations, SaliPhe protected 62.5{\%} of mice against a lethal challenge of a mouse-adapted influenza strain, while BafA at cytotoxic concentrations showed essentially no protection against infection with IAV (SaliPhe vs. BafA P < 0.001). CONCLUSIONS AND IMPLICATIONS Our results show that a distinct binding site of the proton translocation domain of cellular v-ATPase can be selectively targeted by a new generation v-ATPase inhibitor with reduced toxicity to treat influenza virus infections, including multi-resistant strains. Treatment strategies against influenza that target host cellular proteins are expected to be more resistant to virus mutations than drugs blocking viral proteins.",
keywords = "archazolid B, bafilomycin A1, concanamycin A, H5N1, influenza A virus, pandemic H1N1, salicylihalamide A derivatives, saliphenylhalamide, v-ATPase, v-ATPase inhibitor",
author = "M{\"u}ller, {Konstantin H.} and Kainov, {Denis E.} and {El Bakkouri}, Karim and Xavier Saelens and {De Brabander}, {Jef K.} and Christian Kittel and Elisabeth Samm and Muller, {Claude P.}",
year = "2011",
month = "9",
doi = "10.1111/j.1476-5381.2011.01346.x",
language = "English (US)",
volume = "164",
pages = "344--357",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections

AU - Müller, Konstantin H.

AU - Kainov, Denis E.

AU - El Bakkouri, Karim

AU - Saelens, Xavier

AU - De Brabander, Jef K.

AU - Kittel, Christian

AU - Samm, Elisabeth

AU - Muller, Claude P.

PY - 2011/9

Y1 - 2011/9

N2 - BACKGROUND AND PURPOSE Cellular vacuolar ATPases (v-ATPase) play an important role in endosomal acidification, a critical step in influenza A virus (IAV) host cell infection. We investigated the antiviral activity of the v-ATPase inhibitor saliphenylhalamide (SaliPhe) and compared it with several older v-ATPase inhibitors concanamycin A, bafilomycin A1, (BafA) and archazolid B targeting the subunit c of the V 0 sector. EXPERIMENTAL APPROACH An in vitro assay was devised to quantify the anti-influenza effect of v-ATPase inhibitors by measuring green fluorescent protein fluorescence of a reporter IAV. These data were combined with cytotoxicity testing to calculate selectivity indices. Data were validated by testing v-ATPase inhibitors against wild-type IAV in vitro and in vivo in mice. KEY RESULTS In vitro SaliPhe blocked the proliferation of pandemic and multidrug resistant viruses at concentrations up to 51-fold below its cytotoxic concentrations. At essentially non-toxic concentrations, SaliPhe protected 62.5% of mice against a lethal challenge of a mouse-adapted influenza strain, while BafA at cytotoxic concentrations showed essentially no protection against infection with IAV (SaliPhe vs. BafA P < 0.001). CONCLUSIONS AND IMPLICATIONS Our results show that a distinct binding site of the proton translocation domain of cellular v-ATPase can be selectively targeted by a new generation v-ATPase inhibitor with reduced toxicity to treat influenza virus infections, including multi-resistant strains. Treatment strategies against influenza that target host cellular proteins are expected to be more resistant to virus mutations than drugs blocking viral proteins.

AB - BACKGROUND AND PURPOSE Cellular vacuolar ATPases (v-ATPase) play an important role in endosomal acidification, a critical step in influenza A virus (IAV) host cell infection. We investigated the antiviral activity of the v-ATPase inhibitor saliphenylhalamide (SaliPhe) and compared it with several older v-ATPase inhibitors concanamycin A, bafilomycin A1, (BafA) and archazolid B targeting the subunit c of the V 0 sector. EXPERIMENTAL APPROACH An in vitro assay was devised to quantify the anti-influenza effect of v-ATPase inhibitors by measuring green fluorescent protein fluorescence of a reporter IAV. These data were combined with cytotoxicity testing to calculate selectivity indices. Data were validated by testing v-ATPase inhibitors against wild-type IAV in vitro and in vivo in mice. KEY RESULTS In vitro SaliPhe blocked the proliferation of pandemic and multidrug resistant viruses at concentrations up to 51-fold below its cytotoxic concentrations. At essentially non-toxic concentrations, SaliPhe protected 62.5% of mice against a lethal challenge of a mouse-adapted influenza strain, while BafA at cytotoxic concentrations showed essentially no protection against infection with IAV (SaliPhe vs. BafA P < 0.001). CONCLUSIONS AND IMPLICATIONS Our results show that a distinct binding site of the proton translocation domain of cellular v-ATPase can be selectively targeted by a new generation v-ATPase inhibitor with reduced toxicity to treat influenza virus infections, including multi-resistant strains. Treatment strategies against influenza that target host cellular proteins are expected to be more resistant to virus mutations than drugs blocking viral proteins.

KW - archazolid B

KW - bafilomycin A1

KW - concanamycin A

KW - H5N1

KW - influenza A virus

KW - pandemic H1N1

KW - salicylihalamide A derivatives

KW - saliphenylhalamide

KW - v-ATPase

KW - v-ATPase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=80051966225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051966225&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01346.x

DO - 10.1111/j.1476-5381.2011.01346.x

M3 - Article

VL - 164

SP - 344

EP - 357

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -